GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

GSK (LSE:GSK) has been drawing investor attention after recent share price moves and updated return figures, prompting a ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

UK pharma major GSK today announced positive results from its two pivotal Phase III trials, B-Well 1 [NCT05630807] and B-Well ...

GSK (NYSE:GSK) just posted the kind of late-stage result drugmakers hope for. The company said its experimental hepatitis B ...

GSK and Ionis report strong Phase 3 results for a hepatitis B drug that improved cure rates and could support regulatory filings in early 2026.

GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of ...

European Commission approves GSK’s recombinant zoster vaccine, Shingrix in prefilled syringe: London, UK Thursday, January 8, 2026, 09:00 Hrs [IST] GSK plc announced the Europea ...

GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 ...